Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...
In patients with COPD both with or without heart failure, AF episodes rise around the time patients are hospitalized for ...
Health on MSN5d
What Is Acute Kidney Failure? Everything To KnowMedically reviewed by Kashif J. Piracha, MD Medically reviewed by Kashif J. Piracha, MD Acute kidney failure, now known as ...
The surprise finding hints that anti–acid reflux therapy may provide benefit in COPD, possibly by reducing micro-aspirations, ...
Zacks.com on MSN18d
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPDSanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...
The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...
The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...
Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...
Exacerbations are recognized to be crucial acute events that are associated with increased hospitalization rates and ...
Krunal Patel, MD, Temple University Hospital, highlights CHEST 2024 data revealing why timing matters with acute pulmonary embolism (PE) intervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback